SCHEMBL1938394

SCHEMBL1938394

COCc1cc(COC)c(C(=O)C=Cc2ccccc2)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
KMT2A Q03164 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
MEN1 O00255 1/20 0.60
KCNA3 P22001 1/20 0.60
TP53 P04637 1/20 0.59
CYP3A4 P08684 1/20 0.59
ATM Q13315 1/20 0.59
HSD17B10 Q99714 1/20 0.59
CYP19A1 P11511 1/20 0.54
CYP2C9 P11712 1/20 0.54
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
CYP2C19 P33261 1/20 0.54
ABCB1 P08183 1/20 0.52
ABCG2 Q9UNQ0 1/20 0.51
TNFRSF1A P19438 2/20 0.51
TDP1 Q9NUW8 1/20 0.50
CYP1A1 P04798 1/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1938391 1.00 MAPT (0.60) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL2285234 0.89 TDP1 (0.65) MAPTKMT2AMEN1TP53CYP3A4
SCHEMBL1938373 0.88 MAPT (0.75) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL1938375 0.88 MAPT (0.75) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL30384473 0.88 MAPT (0.75) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL2282009 0.81 MAPT (0.66) MAPTKMT2AMEN1CYP3A4CYP2C9
SCHEMBL25203552 0.79 MAPT (0.86) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL25203549 0.79 MAPT (0.86) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL3895258 0.79 TP53 (0.54) MAPTKMT2AMEN1TP53CYP3A4
SCHEMBL29101760 0.78 MAPT (0.49) MAPTKMT2ANPSR1MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed
EP-2330906-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES University Of Louisville Research Foundation, Inc. (US) 2011-06-15 EP disclosed
WO-2010019861-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES TERT, TYMS, NISCH MAPT 2194/4885KMT2A 1587/4885NPSR1 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.